Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Debt (2016 - 2025)

Historic Total Debt for Arrowhead Pharmaceuticals (ARWR) over the last 11 years, with Q4 2025 value amounting to $203.1 million.

  • Arrowhead Pharmaceuticals' Total Debt fell 5039.06% to $203.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $203.1 million, marking a year-over-year decrease of 5039.06%. This contributed to the annual value of $254.9 million for FY2025, which is 3517.45% down from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Total Debt of $203.1 million as of Q4 2025, which was down 5039.06% from $254.9 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Total Debt's 5-year high stood at $409.4 million during Q4 2024, with a 5-year trough of $203.1 million in Q4 2025.